Filtered By:
Condition: Hemorrhagic Stroke
Drug: Activase

This page shows you your search results in order of date.

Order by Relevance | Date

Total 351 results found since Jan 2013.

Intracranial hemorrhage in large vessel occlusion patients receiving endovascular thrombectomy with or without intravenous alteplase: a secondary analysis of the DIRECT-MT trial
Conclusions Our data showed that in the DIRECT-MT trial, alteplase did not increase overall ICH for large vessel occlusion patients treated with thrombectomy, but it increased the parenchymal hematoma rate.
Source: Journal of NeuroInterventional Surgery - September 15, 2023 Category: Neurosurgery Authors: Hu, X., Zhou, Y., Ospel, J., Yao, F., Liu, Y., Wang, H., Li, B., Hui, P., Yang, P., Zhang, Y., Zhang, L., Li, Z., Xing, P., Shi, H., Han, H., Wang, S., Fang, Q., Liu, J., for the Direct-MT investigators Tags: Open access, Ischemic stroke Source Type: research

Influence of time metrics on the treatment effect of intravenous alteplase prior to endovascular treatment in MR CLEAN-NO IV
Conclusion In MR CLEAN-NO IV, the effect of IVT prior to EVT was not modified by OTR, OTN, DTG or NTG times. Our results do not support the use of these metrics to guide IVT treatment decisions prior to EVT in comprehensive stroke centres. Trial registration number ISRCTN80619088.
Source: Journal of NeuroInterventional Surgery - August 29, 2023 Category: Neurosurgery Authors: Rinkel, L. A., Treurniet, K. M., Kappelhof, M., LeCouffe, N. E., Bruggeman, A. A. E., Nieboer, D., van Zwam, W. H., Uyttenboogaart, M., Dippel, D. W. J., Emmer, B. J., Roos, Y. B. W. E. M., Majoie, C. B. L. M., Coutinho, J. M., on behalf of the MR CLEAN-N Tags: Ischemic stroke Source Type: research

Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial
Conclusions We found no evidence that the effect of bridging IVT on functional independence is modified by overall or in-hospital treatment delays. Considering its low power, this subgroup analysis could have missed a clinically important effect, and exploratory analysis of secondary clinical outcomes indicated a potentially favorable effect of IVT with shorter in-hospital delays. Heterogeneity of the IVT effect size before MT should be further analyzed in individual patient meta-analysis of comparable trials. Trial registration number URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03192332
Source: Journal of NeuroInterventional Surgery - August 29, 2023 Category: Neurosurgery Authors: Meinel, T. R., Kaesmacher, J., Buetikofer, L., Strbian, D., Eker, O. F., Cognard, C., Mordasini, P., Deppeler, S., Mendes Pereira, V., Albucher, J. F., Darcourt, J., Bourcier, R., Guillon, B., Papagiannaki, C., Costentin, G., Sibolt, G., Räty, S., Tags: Open access, Ischemic stroke Source Type: research

Comparing adverse Events of tenecteplase and alteplase: A Real-World analysis of the FDA adverse Event Reporting System (FAERS)
CONCLUSION: This study identified and compared signals of ADRs associated with tenecteplase and alteplase, although tenecteplase is as effective as alteplase and has advantages such as ease of use and affordability, it cannot replace alteplase in the treatment of AIS until its safety profile is fully recognized. Additionally, previously unreported ocular ADRs and pneumonia were identified, providing valuable insights into the relationship between ADRs and the use of these thrombolytic drugs. These findings underscore the importance of continuous monitoring and effective detection of AEs to ultimately enhance the safety of ...
Source: Expert Opinion on Drug Safety - August 9, 2023 Category: Drugs & Pharmacology Authors: Fang-E Shi Zhe Yu Chengyue Sun Peiliang Gao Haiyan Zhang Jihong Zhu Source Type: research

Low-dose intravenous recombinant tissue plasminogen activator in acute ischemic stroke without large vessel occlusion screened by 3T MRI
CONCLUSIONS: Our study indicates the efficacy and safety of low-dose rTPA treatment for AIS without LVO within 4.5 hours. Patient selection for rTPA by 3T MRI decreased complications and mortality.PMID:37522667 | DOI:10.26355/eurrev_202307_33126
Source: European Review for Medical and Pharmacological Sciences - July 31, 2023 Category: Drugs & Pharmacology Authors: Q-S Huynh C-C Tran H-T Nguyen-Thi T-T Nguyen H-L Phan-Thi D-T Luu-Dang M-T Le M-D Nguyen Source Type: research